GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3030)

  • GN10717 structure
    GN10717Sanguinarine
    CAS: 2447-54-3
    Purity: >98.00%
  • GN10727 structure
    GN10727Forsythoside B
    CAS: 81525-13-5
    Purity: >98.00%

    Forsythoside B es un glucósido feniletanol aislado de las hojas de la planta medicinal tradicional china Forsythia suspensa.Tiene múltiples actividades biológicas y puede utilizarse para tratar enfermedades inflamatorias y promover la circulación sanguínea.

  • GN10732 structure
    GN10732Oroxin B
    CAS: 114482-86-9
    Purity: >99.50%
  • GN10733 structure
    GN10733Carnosic acid
    CAS: 3650-09-7
    Purity: >97.00%
  • GN10734 structure
    GN10734Polyphyllin B
    CAS: 76296-72-5
    Purity: >98%
  • GN10740 structure
    GN10740Tetrahydropalmatine
    CAS: 10097-84-4
    Purity: >99.00%
  • GN10741 structure
    GN10741Garcinone D
    CAS: 107390-08-9
    Purity: >98.00%
  • GN10751 structure
    GN10751Dictamnine
    CAS: 484-29-7
    Purity: >98.50%
  • GN10776 structure
    GN10776Obacunone
    CAS: 751-03-1
    Purity: >98.00%
  • GN10778 structure
    GN10778Picroside II
    CAS: 39012-20-9
    Purity: >95.00%
  • GN10783 structure
    GN10783(R) Ginsenoside Rh2
    CAS: 112246-15-8
    Purity: >98.00%
  • GN10788 structure
    GN10788Cucurbitacin IIb
    CAS: 50298-90-3
    Purity: >98.00%
  • GN10797 structure
    GN10797Tangeretin
    CAS: 481-53-8
    Purity: >98.00%

    Tangeretin es un compuesto de flavona naturalmente polimetoxilado extraído de la cáscara de cítricos y actúa como inhibidor de Notch-1

  • GN10800 structure
    GN1080020(S)-NotoginsenosideR2
    CAS: 80418-25-3
    Purity: >98.00%
  • GN10802 structure
    GN10802Brazilin
    CAS: 474-07-7
    Purity: >98.00%
  • GN10805 structure
    GN10805Protopanaxdiol
    CAS: 30636-90-9
    Purity: >98.00%
  • GP10028 structure
  • GP10036 structure
    GP10036p53 tumor suppressor fragment
    Purity: >98%

    Regulates cell cycle

  • GC12407 structure
    GC12407Z-IETD-FMK
    CAS: 210344-98-2
    Purity: >98.00%

    Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) es un inhibidor selectivo y permeable a las células de la caspasa-8.

  • GC16990 structure
    GC16990Z-LEHD-FMK
    CAS: 210345-04-3
    Purity: >98.00%

    Z-LEHD-FMK es un inhibidor selectivo e irreversible de la caspasa-9, protege contra la lesiÓn por reperfusiÓn letal y atenÚa la apoptosis.

  • GC11908 structure
    GC11908Cisplatin
    CAS: 15663-27-1
    Purity: >98.00%

    Cisplatin es uno de los mejores y primeros fármacos quimioterapéuticos basados en metales, utilizado para una amplia gama de cánceres sólidos como el cáncer testicular, de ovario, de vejiga, de pulmón, de cuello uterino, de cabeza y cuello, cáncer gástrico y otros tipos de cáncer.

  • GC13473 structure
    GC13473Lenalidomide hemihydrate
    CAS: 847871-99-2
    Purity: >99.50%

    El hemihidrato de lenalidomida (CC-5013 hemihidrato), un derivado de la talidomida, actÚa como pegamento molecular. Lenalidomida hemihidrato es un inmunomodulador activo por vÍa oral. El hemihidrato de lenalidomida (CC-5013 hemihidrato) es un ligando de la ubiquitina E3 ligasa cereblon (CRBN) y provoca la ubiquitinaciÓn selectiva y la degradaciÓn de dos factores de transcripciÓn linfoides, IKZF1 e IKZF3, por la ubiquitina ligasa CRBN-CRL4. El hemihidrato de lenalidomida (CC-5013 hemihidrato) inhibe especÍficamente el crecimiento de linfomas de células B maduras, incluido el mieloma mÚltiple, e induce la liberaciÓn de IL-2 de las células T.

  • GC15035 structure
    GC15035PM00104
    CAS: 308359-57-1
    Purity: >98%

    Potent antimyeloma agent

  • GC15036 structure
    GC15036Raltegravir potassium salt
    CAS: 871038-72-1
    Purity: >98.00%

    Raltegravir (MK 0518) potÁsico es un potente inhibidor de la integrasa (IN), que se utiliza para tratar la infecciÓn por VIH.